RAF1 and cancer: Because c-Raf plays an important role in JCPyV infection, and the safety of targeting c-Raf has already been established with cancer therapies like sorafenib, we sought to characterize blood–brain-barrier-permeable c-Raf inhibitors as novel anti-JCPyV agents.